- Home
- DOUG vs CRBP Comparison
DOUG vs CRBP Comparison
Compare DOUG & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | CRBP |
|---|---|---|
| Founded | 1911 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 184.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DOUG | CRBP |
|---|---|---|
| Price | $1.81 | $8.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 435.4K | ★ 447.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.53 | $7.12 |
| 52 Week High | $3.19 | $20.56 |
Technical Indicators
Market Signals| Indicator | DOUG | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 50.69 |
| Support Level | $1.73 | $7.86 |
| Resistance Level | $1.84 | $9.73 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 27.69 | 35.51 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.